ibrutinib,venetoclax
janssen,abbvie,roche
['ibru', 'leukemia', 'janssen']
#janssen reported new #imbruvica (#ibrutinib) data in fixed-duration combination regimen presented at #eha22 shows deep, durable response at three years in untreated #chroniclymphocyticleukemia 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.